Loading news...
RFIL, BWMX, FET, KRYS and MAMA are five stocks showing sharp recent price strength as markets start 2026 strong.
Krystal Biotech (KRYS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Krystal Biotech is upgraded to Strong Buy, driven by Vyjuvek's commercial success and a robust catalyst-rich pipeline. KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to deliver four rare disease drugs by 2030. Recent positive Phase 1 data for KB407 in cystic fibrosis derisks inhaled delivery, enhancing confidence in upcoming AATD and NSCLC programs.
ISSC, AUGO, OWLT, KRYS and IDN are among a select group of stocks showing strong recent price momentum.
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business.
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) has been given an average recommendation of "Buy" by the eleven analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:00 am ET and host investor meetings throughout the day.
Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 7.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,529 shares of the company's stock after buying an additional 472 shares during the
Campbell and CO Investment Adviser LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,991 shares of the company's stock, valued at approximately
Krystal Biotech is rated a buy after a strong Vyjuvek launch, but the current valuation reflects premium margins and aggressive global expansion projections. Vyjuvek's US sales growth has plateaued, but international rollouts in Europe and Japan are expected to drive further sales growth, with management targeting $1B in peak sales. KRYS pipeline catalysts include KB803 (ophthalmology), KB407 (cystic fibrosis), and KB801 (neurotrophic keratitis), with key data readouts over the next year.
Aviva PLC raised its stake in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) by 9.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,575 shares of the company's stock after purchasing an additional 319 shares during the quarter.
AlphaQuest LLC trimmed its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 65.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 579 shares of the company's stock after selling 1,084 shares during the period. AlphaQuest LLC's holdings
Krystal Biotech (KRYS) reported strong Q3 results, with Vyjuvek delivering $97.8M revenue, 96% gross margin, and a new at-home use label. KRYS's disciplined operating expenses and robust cash position support profitability, while pipeline progress in cystic fibrosis and DEB eye therapy adds optionality. The FDA's Platform Technology Designation for KRYS's HSV-1 vector accelerates development, enhancing competitive positioning in gene therapy markets.
Krystal Biotech, Inc. ( KRYS ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Stephane Paquette - Vice President of Corporate Development Krish Krishnan - Founder, Chairman, President & CEO Laurent Goux - Senior VP & GM of Europe Suma Krishnan - Founder, President of R&D and Director Kathryn Romano - Executive VP & Chief Accounting Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Ritu Baral - TD Cowen, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Alexa Deemer - Cantor Fitzgerald & Co., Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Presentation Operator Thank you for standing by, and welcome to the Krystal Biotech Third Quarter 2025 Earnings Call.